Bliss GVS Pharma Limited

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has informed the Exchange regarding re-classification from the promoter and promoter group category to the public category, following the consummation of a transaction and completion of an open offer.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has published a newspaper advertisement regarding the extension of a special window for re-lodging transfer requests of physical shares, as per SEBI regulations.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has informed the Exchange about a Certificate under Regulation 74(5) SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on October 01, 2026, where the Board of Directors approved the adoption of Senior Executive Employee Stock Option Policy 2026 and Employee Stock Option Policy 2026, and granted stock options equal to or exceeding 1% of issued capital to identified employees.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, effective from October 01, 2026, until the announcement of the Unaudited Financial Results for the quarter and half year ended September 30, 2026.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has informed the Exchange about the resignation of a Director/KMP/SMP.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has informed the Exchange regarding Outcome of the 2nd Board Meeting held on September 28, 2026, where the Board has taken note of the re-classification of the erstwhile members of the promoter and promoter group of the Company from the “promoter/promoter group” category to the “public” category, in accordance with Regulation 31A(10) of the SEBI Listing Regulations.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has informed the Exchange about change in Management pursuant to the Change in Control of the Company. The Board of Directors has appointed three new directors and noted the resignation of the Managing Director.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on September 28, 2026, relating to the consummation of the transaction contemplated in the share purchase agreement dated May 23, 2026. The Board has approved the appointment of three new directors, including Mr. Hetul Krishnakant Mehta, Mr. Amar Dilip Shah, and Mr. Pramod Badrinarayan Kasat, and noted the resignation of Mr. Narsimha Shibroor Kamath as Managing Director.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has submitted the Scrutinizer's report of the Postal Ballot, disclosing the voting results. The company had appointed a Scrutinizer to ensure a fair and transparent voting process for the Ordinary Resolution regarding the appointment of a Non-Executive and Non-Independent Director, Mr. Santosh Parab.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has informed the Exchange regarding the ESOP Allotment Committee's approval of allotting 55,250 equity shares to eligible employees under the Bliss GVS ESOP-2019 plan, increasing the issued, subscribed & paid-up share capital from 10,62,75,223 to 10,63,30,472 equity shares.

Bliss GVS Pharma Limited

Anupam Rasayan India Limited and Mates Visa Consultancy Private Limited have made an open offer to acquire up to 26% of Bliss GVS Pharma Limited's expanded voting share capital from public shareholders.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has informed the Exchange about the extension of a special window for re-lodging transfer requests of physical shares, as per SEBI regulations.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has submitted a copy of newspaper publication regarding the advertisement of the postal ballot notice, as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has informed the Exchange regarding Notice of Postal Ballot

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has published a copy of a newspaper advertisement regarding the extract of its un-audited standalone and consolidated financial results for the quarter ended June 30, 2026.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has informed the Exchange about General Updates regarding the grant of options under Bliss GVS Pharma Limited - Employee Stock Options Plan 2019 to eligible employees.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has announced its unaudited financial results for the quarter ended June 30, 2026, along with the Limited Review Report and a draft of the Postal Ballot Notice for the appointment of a new Director.

Bliss GVS Pharma Limited

Bliss GVS Pharma Limited has informed the Exchange regarding allotment of 31,250 securities pursuant to ESOP/ESPS at its meeting held on August 11, 2026, increasing the issued, subscribed & paid-up share capital of the Company.

Bliss GVS Pharma Limited

SBI Capital Markets Ltd has submitted a pre-offer advertisement and corrigendum to the detailed public statement for the attention of public shareholders of Bliss GVS Pharma Limited.